PT-141 works on your brain, not your blood vessels. That's the thing most people get wrong about it — they compare it to Viagra or Cialis and expect a similar experience. It's not similar at all.
Where PDE5 inhibitors work by increasing blood flow to the genitals, PT-141 (bremelanotide) activates melanocortin receptors in the central nervous system — specifically MC3R and MC4R in the hypothalamus. The result is an increase in sexual motivation and arousal from the inside out. It works on desire, not just mechanics. That distinction matters, especially for people whose issue isn't physical blood flow but diminished libido or difficulty becoming aroused.
This guide covers exactly how to dose PT-141, when to take it, what to expect, and the differences between administration routes.
🔑 Key Takeaways
- PT-141 is a melanocortin receptor agonist (MC3R/MC4R) — it works centrally on arousal, not peripherally on blood flow
- Onset is 45–90 minutes; effects last 6–12 hours
- Starting dose: 0.5mg; standard dose: 1–2mg; max recommended: 2mg per use
- Nausea is the most common side effect — usually dose-dependent and manageable
- Women often respond at lower doses than men (0.5–1mg is frequently sufficient)
- Intranasal and subcutaneous routes both work; subQ provides more consistent absorption
PT-141 Dosage: The Numbers
Start low. This is not a "more is better" situation — higher doses increase nausea and other side effects without proportionally increasing the sexual effects. The sweet spot for most people is 1–2mg.
| Dose | Who It's For | Timing Before Activity | Notes |
|---|---|---|---|
| 0.5mg | First-time users, women, sensitive individuals | 60–90 minutes | Test dose to assess tolerance; many women find this sufficient |
| 1mg | Standard dose, both men and women | 60–90 minutes | Best balance of effect vs. side effects for most users |
| 1.75mg | FDA-approved dose for women (HSDD) | 45–90 minutes | Clinical dose; well-studied in women |
| 2mg | Men or users who found lower doses insufficient | 60 minutes | Max recommended; higher doses increase nausea sharply without better results |
Frequency: Most protocols suggest using PT-141 no more than once every 72 hours (3 days). More frequent use is not well-studied and may reduce effectiveness over time. Many people find once-weekly or occasional use most sustainable.
Men vs Women: Does the Dose Differ?
Yes, and meaningfully so. Women tend to respond to PT-141 at lower doses — 0.5–1mg is often fully effective. The FDA's approved dose for women is 1.75mg, but community and research data suggest many women get the desired effect at 1mg or below.
For men, the effective range is typically 1–2mg. Below 1mg, men often report minimal effect. Above 2mg, side effects increase noticeably.
The physiological reason isn't completely understood, but it likely relates to differences in melanocortin receptor density and baseline hormonal environment. The practical upshot: women should start at 0.5mg and only increase if the response is insufficient. Men should start at 1mg.
Intranasal vs Subcutaneous: Which Route Is Better?
PT-141 was originally developed as an intranasal spray (the nasal spray formulation was tested in early clinical trials but wasn't pursued commercially). Subcutaneous injection is the route used in the FDA-approved product and most research.
| Subcutaneous Injection | Intranasal | |
|---|---|---|
| Bioavailability | ~100% (direct absorption) | ~30–40% (variable) |
| Onset | 45–90 minutes | 30–60 minutes (faster, less predictable) |
| Duration | 6–12 hours | 4–8 hours |
| Dosing consistency | High | Lower — nasal absorption varies |
| Side effects | Nausea, flushing at injection site | Similar, plus nasal irritation |
| Recommended? | Yes — consistent and well-studied | Sometimes used; less predictable |
SubQ is the better route for most people. The injection is shallow (abdominal or thigh), the dose is exact, and you know what to expect each time. Intranasal can work but bioavailability is inconsistent — you might need to dose higher and still get a weaker effect.
How to Reconstitute PT-141
PT-141 comes as a lyophilized (freeze-dried) powder. You need to reconstitute it before use.
Gather Supplies
You need: PT-141 vial (10mg), bacteriostatic water, 1ml insulin syringes (29–31 gauge), alcohol wipes. Do not use sterile water — bacteriostatic water prevents bacterial growth during storage.
Add Bacteriostatic Water
For a 10mg vial: add 2ml of bacteriostatic water. This gives you a 5mg/ml concentration (each 0.1ml = 0.5mg). Alternatively, add 1ml for 10mg/ml (each 0.1ml = 1mg). Choose whatever math is easier for your target dose.
Inject the Water Gently
Wipe the vial top with an alcohol wipe. Insert the needle and inject the water against the glass wall of the vial — not directly onto the powder. This prevents foaming and degradation.
Let It Dissolve
Gently swirl (don't shake) until the powder is fully dissolved. Should take 30–60 seconds. The solution should be clear and colorless.
Store Correctly
Reconstituted PT-141 should be refrigerated (2–8°C / 36–46°F) and used within 30 days. Label the vial with the date of reconstitution.
Draw and Inject
Wipe the injection site (lower abdomen or thigh) with an alcohol wipe. Pinch the skin, insert the needle at 45–90 degrees, inject slowly, and withdraw. Apply gentle pressure. Do not inject into muscle.
Side Effects
PT-141's side effects are generally mild and dose-dependent. The most common:
Nausea — affects roughly 40% of users at 1.75mg. Usually hits 30–60 minutes after injection and lasts 1–2 hours. Eating a light meal before dosing helps. Ginger tea or ginger chews work well. Taking a lower dose on the first use lets you assess your sensitivity.
Facial flushing — warmth and redness in the face, neck, and chest. Very common (estimated 20–40% of users). Not dangerous; it fades within an hour. Some people describe it as uncomfortable; others barely notice.
Spontaneous erections — in men, PT-141 can cause erections unrelated to arousal or stimulation, especially in the first few hours. This is essentially the mechanism working. Not a side effect in the clinical sense, but unexpected in some contexts.
Blood pressure changes — transient increases in blood pressure of 6–10 mmHg systolic have been observed in clinical trials. This is why the FDA recommends monitoring blood pressure, and why people with cardiovascular disease should discuss with a provider before using PT-141.
Headache — reported by about 11% of users in trials. Usually mild and self-limiting.
Stacking PT-141 with Oxytocin
PT-141 activates arousal and sexual motivation. Oxytocin — the "bonding hormone" — deepens emotional connection and can intensify physical sensation. The combination is increasingly popular among people looking to enhance intimacy rather than just physical performance.
The stack: 1mg PT-141 subcutaneously + 15–25 IU oxytocin intranasally, both taken 45–60 minutes before activity.
Oxytocin intranasally clears quickly — onset within 15–30 minutes, duration 1–2 hours. The combined effect: PT-141 drives motivation and arousal; oxytocin adds the emotional/sensory layer. Anecdotally, people describe more immersive, connected experiences.
There's no published human trial on this specific combination, so protocol is based on community data and individual components' known mechanisms. Both are low-risk in terms of serious adverse effects at typical doses.
💡 Timing Note
Because PT-141 has a longer onset (45–90 min) and oxytocin peaks faster (~30 min), many people take PT-141 first, then oxytocin 15–20 minutes later, so both reach peak effect around the same time.
Where to Get PT-141 for Research
Ascension Peptides carries PT-141 10mg vials as part of their research peptide catalog. Their products are third-party tested and shipped with CoA documentation. For research use.